High-powered radioluminescence microscopy can home in on extremely scarce malignant cells among billions of normal cells in a blood sample. Leveraging the molecular imaging of circulating tumor cells (CTCs) could mean early detection of metastasis and the potential to improve survival for patients with several varieties of cancer, according to a study presented today during the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2014 Annual Meeting press conference.

18F-DTBZ PET is a potential imaging biomarker for measuring dopaminergic degeneration in vivo and monitoring Parkinson disease (PD) severity, according to a study published by JAMA Neurology on June 9. 

ST. LOUIS--As the weekend opening of the 61st Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting sunsets, three more days full of meetings, presentations and exhibitions approach. See an SNMMI-hosted audiovisual montage of highlights and attendee interviews from the first two days of the conference.

Los Angeles-based biomedical firm ImaginAb has announced June 3 that the company is working with researchers at the University of California and has settled on a technology licensing agreement for the developmentof investigational immune cell PET agents.

ImaginAb, Inc., in collaboration with Memorial Sloan-Kettering Cancer Center (MKSCC), will be presenting initial clinical data with an anti-PSMA recombinant antibody fragment (a "minibody") derived from the huJ591 monoclonal antibody, in patients with metastatic prostate cancer. The presentation of this initial data coincides with the Company's preparation to expand the clinical development of this promising imaging agent in the US and internationally.

Remediation of Parkinson’s via stem cell transplantation has been verified and dopamine transporter (DAT) expression was found to be normal not just in short-term studies, but for 4-14 years after transplantation of dopamine neurons, according to a study published June 5 in Cell Reports.

The new cancer center paradigm provides genetic tests not just for experimental research, but as a clinical standard. In this glimpse by Bloomberg, Memorial Sloan Kettering Cancer Center shows off a new laboratory opened just weeks ago where patients' biopsies will be tested for 341 mutations associated with disease.

Bethesda, MD (June 3, 2014) The American Society of Nuclear Cardiology (ASNC) will be offering a Nuclear Cardiology Board Exam Preparation Course from July 11-13 at the Intercontinental Hotel Chicago O'hare in Rosemont, Ill.